EUSA Sylvant Licence Marks Toehold Into US Rare Disease Market
Six months after selling its critical care business to refocus on rare diseases and oncology, EUSA Pharma has made its first move into those markets by licensing a Janssen product for a rare blood disorder.
You may also be interested in...
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
EUSA Pharma, initially formed in 2006 but later acquired by Jazz Pharmaceuticals in 2012, was reborn last year with a fresh new focus on specialty products in the oncology space. Business development director, Benjamin Owens, spoke with Scrip reporter Lucie Ellis about EUSA's big plans for global expansion. The pharma will target Spain, Italy and the Nordics in the near future and is also focused on securing a strong US presence through collaborations and acquisitions.
Johnson & Johnson subsidiary Janssen gained FDA approval on 23 April for Sylvant (siltuximab), the first drug in the US to treat patients with multicentric Castleman's disease (MCD), a rare blood disorder in which lymphocytes are over-produced, leading to enlarged lymph nodes, and which also can affect the lymphoid tissue of internal organs, causing the liver, spleen or other organs to enlarge.